Page last updated: 2024-10-24

response to Gram-negative bacterium

Definition

Target type: biologicalprocess

Any process that results in a change in state or activity of a cell or an organism (in terms of movement, secretion, enzyme production, gene expression, etc.) as a result of a stimulus from a Gram-negative bacterium. [PMID:23664307]

The response to Gram-negative bacteria is a complex and multi-faceted process involving a coordinated effort by the host's immune system to recognize, neutralize, and eliminate these pathogens. This process is initiated when the host encounters Gram-negative bacteria, which possess unique structural features that trigger specific immune responses.

The first step involves the recognition of Gram-negative bacteria by the host's innate immune system. This recognition is mediated by pattern recognition receptors (PRRs), which are expressed on various immune cells such as macrophages, neutrophils, and dendritic cells. PRRs recognize pathogen-associated molecular patterns (PAMPs) that are specifically associated with Gram-negative bacteria. These PAMPs include lipopolysaccharide (LPS), a major component of the outer membrane of Gram-negative bacteria, flagellin, the protein subunit of bacterial flagella, and peptidoglycan, a component of the bacterial cell wall.

Upon recognition of PAMPs by PRRs, a cascade of signaling events is initiated, leading to the activation of various transcription factors, including NF-κB and AP-1. These transcription factors induce the expression of a wide range of pro-inflammatory cytokines and chemokines, such as TNF-α, IL-1β, IL-6, and CXCL8. These inflammatory mediators play a crucial role in recruiting immune cells to the site of infection, promoting the elimination of bacteria, and initiating tissue repair.

The recruitment of immune cells to the site of infection is essential for controlling bacterial proliferation. Neutrophils, which are the first responders to bacterial infection, are attracted by chemokines and engulf and kill bacteria through phagocytosis. Macrophages, which arrive later, also phagocytose bacteria and release additional inflammatory mediators to enhance the immune response. Dendritic cells, specialized antigen-presenting cells, capture bacterial antigens and migrate to lymph nodes, where they present these antigens to T cells.

T cells, which are a key component of the adaptive immune response, are activated by antigen-presenting cells and differentiate into various effector T cell subsets, including cytotoxic T lymphocytes (CTLs) and T helper cells. CTLs directly kill bacteria-infected cells, while T helper cells provide support to other immune cells. For example, T helper 1 (Th1) cells produce cytokines such as IFN-γ, which activate macrophages and promote bacterial killing.

The adaptive immune response also involves the generation of antibodies, which are proteins that specifically bind to bacterial antigens. Antibodies can neutralize bacteria by blocking their attachment to host cells, promote phagocytosis by immune cells, and activate complement, a system of proteins that can directly kill bacteria.

The response to Gram-negative bacteria is highly complex and involves a delicate balance between the host's immune system and the bacterial pathogen. An excessive inflammatory response can lead to tissue damage and disease, while an insufficient response can allow bacterial proliferation and systemic infection. Therefore, a well-coordinated and regulated immune response is crucial for effectively controlling Gram-negative bacterial infections.'
"

Proteins (1)

ProteinDefinitionTaxonomy
Tumor necrosis factorA tumor necrosis factor that is encoded in the genome of human. [PRO:DNx]Homo sapiens (human)

Compounds (18)

CompoundDefinitionClassesRoles
mesalaminemesalamine : A monohydroxybenzoic acid that is salicylic acid substituted by an amino group at the 5-position.

Mesalamine: An anti-inflammatory agent, structurally related to the SALICYLATES, which is active in INFLAMMATORY BOWEL DISEASE. It is considered to be the active moiety of SULPHASALAZINE. (From Martindale, The Extra Pharmacopoeia, 30th ed)
amino acid;
aromatic amine;
monocarboxylic acid;
monohydroxybenzoic acid;
phenols
non-steroidal anti-inflammatory drug
way 151693
pentoxifyllineoxopurine
4-(3-butoxy-4-methoxybenzyl)-2-imidazolidinone4-(3-Butoxy-4-methoxybenzyl)-2-imidazolidinone: Inhibitor of phosphodiesterases.methoxybenzenes
roliprampyrrolidin-2-onesantidepressant;
EC 3.1.4.* (phosphoric diester hydrolase) inhibitor
sulfasalazinesulfasalazine : An azobenzene consisting of diphenyldiazene having a carboxy substituent at the 4-position, a hydroxy substituent at the 3-position and a 2-pyridylaminosulphonyl substituent at the 4'-position.

Sulfasalazine: A drug that is used in the management of inflammatory bowel diseases. Its activity is generally considered to lie in its metabolic breakdown product, 5-aminosalicylic acid (see MESALAMINE) released in the colon. (From Martindale, The Extra Pharmacopoeia, 30th ed, p907)
bergeninbergenin: RN refers to (2R-(2alpha,3beta,4alpha,4aalpha,10bbeta))-isomer; structuretrihydroxybenzoic acidmetabolite
marimastatmarimastat : A secondary carboxamide resulting from the foraml condensation of the carboxy group of (2R)-2-[(1S)-1-hydroxy-2-(hydroxyamino)-2-oxoethyl]-4-methylpentanoic acid with the alpha-amino group of N,3-dimethyl-L-valinamide.

marimastat: a matrix metalloproteinase inhibitor active in patients with advanced carcinoma of the pancreas, prostate, or ovary
hydroxamic acid;
secondary carboxamide
antineoplastic agent;
matrix metalloproteinase inhibitor
birb 796aromatic ether;
morpholines;
naphthalenes;
pyrazoles;
ureas
EC 2.7.11.24 (mitogen-activated protein kinase) inhibitor;
immunomodulator
ganoderic acid atriterpenoid
ganoderiol fganoderiol F: a ganoderma triterpene from Ganoderma amboinense; structure in first sourcetriterpenoid
1-(phenylmethyl)benzimidazolebenzimidazoles
luteolin-7-glucosideluteolin 7-O-beta-D-glucoside : A glycosyloxyflavone that is luteolin substituted by a beta-D-glucopyranosyl moiety at position 7 via a glycosidic linkage.

luteolin-7-glucoside: has both antiasthmatic and antineoplastic activities; has 3C protease inhibitory activity; isolated from Ligustrum lucidum
beta-D-glucoside;
glycosyloxyflavone;
monosaccharide derivative;
trihydroxyflavone
antioxidant;
plant metabolite
apigetrinapigenin 7-O-beta-D-glucoside : A glycosyloxyflavone that is apigenin substituted by a beta-D-glucopyranosyl moiety at position 7 via a glycosidic linkage.

apigetrin: structure given in first source
beta-D-glucoside;
dihydroxyflavone;
glycosyloxyflavone;
monosaccharide derivative
antibacterial agent;
metabolite;
non-steroidal anti-inflammatory drug
calycosin-7-o-beta-d-glucopyranosidecalycosin-7-O-beta-D-glucoside : A glycosyloxyisoflavone that is calycosin substituted by a beta-D-glucopyranosyl residue at position at 7 via a glycosidic linkage.

calycosin-7-O-beta-D-glucoside: from Radix Astragali
4'-methoxyisoflavones;
7-hydroxyisoflavones 7-O-beta-D-glucoside;
hydroxyisoflavone;
monosaccharide derivative
spd-304SPD-304: structure in first source
ganoderic acid fganoderic acid F: isolated from Ganoderma lucidum; structure in first sourcetriterpenoid
ganoderic acid c2ganoderic acid C2: from the fruiting body of Ganoderma; structure in first sourcetriterpenoid